Continuous Manufacturing Market CAGR To Exceed 6.4% by 2035 | Roots Analysis
The global continuous manufacturing market size is projected to reach USD 4.36 billion by 2035 from USD 2.08 billion in 2023.
Continuous manufacturing involves the production of pharmaceutical drug substance / drug products in a single run, while operating 24×7. In this process, the drug is developed from its base ingredients / raw materials and processed to the final product in one facility, without any hold time.
For decades, pharmaceutical companies have been using batch processing methods for drug manufacturing, wherein a specific quantity of a drug is produced through multiple sequential steps. However, batch processing / batch manufacturing of a drug substance or drug products can be slow and inefficient. As a result, drug developers have begun to adopt continuous manufacturing systems to streamline drug production processes.
According to our Roots Analysis, the global continuous manufacturing market size is projected to reach USD 4.36 billion by 2035 from USD 2.08 billion in 2023, growing at a CAGR of 6.4% in the forecast period 2023-2035.
Continuous Manufacturing Market Segments
Based on the type of drug molecule, the market is segmented into Small Molecules and Biologics.
The small molecules segment led the market for continuous manufacturing, capturing the largest revenue share of more than 50% in 2023.
The biologics segment is anticipated to show the highest growth potential during the forecast period of close to 9% annually.
Based on the purpose of manufacturing, the biologics continuous manufacturing market is segmented into In-House Manufacturing, Contract Manufacturing and Both.
The contract manufacturing segment led the market for biologics continuous manufacturing, capturing the largest revenue share of more than 65% in 2023.
The in-house manufacturing segment is anticipated to show the highest growth potential during the forecast period of over 13% annually.
Based on the purpose of manufacturing, the small molecules continuous manufacturing market is segmented into In-House Manufacturing, Contract Manufacturing and Both.
The in-house manufacturing segment led the market for small molecules continuous manufacturing, capturing the largest revenue share of more than 55% in 2023.
The both in-house and contract manufacturing segment is anticipated to show the highest growth potential during the forecast period of over 7% annually.
Based on the type of product manufactured, the biologics continuous manufacturing market is segmented into Active Pharmaceutical Ingredients and Finished Dosage Forms.
The active pharmaceutical ingredients led the market for biologics continuous manufacturing, capturing the largest revenue share of more than 90% in 2023.
The finished dosage forms segment is anticipated to show the highest growth potential during the forecast period during the forecast period of over 9.5% annually.
Based on the type of product manufactured, the small molecules continuous manufacturing market is segmented into Active Pharmaceutical Ingredients and Finished Dosage Forms.
The finished dosage forms led the market for small molecules continuous manufacturing, capturing the largest revenue share of more than 90% in 2023.
This segment is anticipated to show the highest growth potential during the forecast period as more small molecules manufactured by continuous manufacturing get approved.
Based on the scale of operation, the biologics continuous manufacturing market is segmented into Preclinical / Clinical and Commercial.
The commercial segment led the market for biologics continuous manufacturing, capturing the largest revenue share of more than 80% in 2023.
The preclinical / clinical segment is anticipated to show the highest growth potential during the forecast period of over 9.5% annually.
Based on the scale of operation, the small molecules continuous manufacturing market is segmented into Preclinical / Clinical and Commercial.
The commercial segment led the market for small molecules continuous manufacturing, capturing the largest revenue share of more than 95% in 2023.
The preclinical / clinical segment is anticipated to show the highest growth potential during the forecast period of over 6.5% annually.
Based on the stage of bioprocessing, the biologics continuous manufacturing market is segmented into Upstream Bioprocessing and Downstream Bioprocessing.
The upstream bioprocessing segment led the market for biologics continuous manufacturing, capturing the largest revenue share of more than 90% in 2023.
The downstream bioprocessing segment is anticipated to show the highest growth potential during the forecast period of over 9.5% annually.
Based on company size, the biologics continuous manufacturing market is segmented into Small, Mid-sized, Large and Very Large.
The very large companies led the market for continuous manufacturing, capturing the largest revenue share of more than 55% in 2023.
The large companies segment is anticipated to show the highest growth potential during the forecast period of more than 9% annually.
Based on company size, the small molecules continuous manufacturing market is segmented into Small, Mid-sized, Large and Very Large.
The mid-sized companies led the market for continuous manufacturing, capturing the largest revenue share of more than 85% in 2023.
The large companies segment is anticipated to show the highest growth potential during the forecast period of close to 3.5% annually.
Continuous Manufacturing Market Regional Outlook
Based on the key geographical regions, the continuous manufacturing market can be segmented into three major regions, including North America, Europe and Asia Pacific. Europe is anticipated to capture the majority share of the continuous manufacturing market in 2023 and this trend is likely to remain unchanged during the forecast period. The Asia Pacific is accounted to be the fastest-growing segment of the market.
Key Report Takeaways
§ Presently, close to 60 players are engaged in continuous and semi-continuous manufacturing of biologics, across the globe; most of these players offer contract manufacturing services
§ The current market landscape of continuous biologic manufacturers is fragmented, featuring the presence of both new entrants and established players; majority of these players are based in the US
§ Owing to the rise in demand for biologics, service providers and drug innovators are upgrading their technical expertise to efficiently manufacture high quality products using continuous manufacturing techniques
§ Close to 50 small molecule manufacturers claim to have expertise in continuous manufacturing; most of these players are large or very large firms
§ Over 40% of the small molecule manufacturers offer continuous upstream processing; majority of these players provide contract manufacturing services at all three scales of operation
§ In pursuit of building a competitive edge in this field, stakeholders are actively upgrading their existing capabilities and adding new competencies in order to enhance their respective portfolios
§ The growing interest in this domain is evident from the rise in partnership activity; in fact, the maximum number of collaborations related to continuous manufacturing were inked in 2023
§ Industry players are putting extensive efforts to expand their existing capacities and capabilities for both clinical and commercial scale continuous manufacturing of biologics and small molecules
§ Since 2020, close to 700 patents have been filed / granted by various stakeholders in order to protect the intellectual property generated within this domain; close to 30% of patents were published in 2022
§ Grants worth over USD 45 million, disbursed across 65+ instances, have been awarded for research related to continuous manufacturing; more than 30% of these grants extend a support period of up to five years
§ The continuous biological manufacturing market is likely to grow at a CAGR of 8.8%, till 2035; presently, majority of the market share is occupied by upstream bioprocessing followed by downstream bioprocessing
§ The continuous small molecules manufacturing market is anticipated to grow at a CAGR of 3.4%, till 2035; North America is expected to capture the majority share (over 50%) of the market by 2035
Continuous Manufacturing Market Key Players
Examples of key companies engaged in continuous manufacturing market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Abbvie Contract Manufacturing, ACG Group, Boehringer Ingelheim, Corden Pharma, Glatt Group, Kaneka, Phlow and WuXi Biologics.
About Roots Analysis
Roots Analysis is a global leader in the market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.
Contact Details
Gaurav Chaudhary
Email: sales@rootsanalysis.com
